Cargando…

Low-grade lymphoma: Beyond fludarabine-single therapy

Detalles Bibliográficos
Autor principal:	Park, Eunkyung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2011
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208193/ https://www.ncbi.nlm.nih.gov/pubmed/22065965 http://dx.doi.org/10.5045/kjh.2011.46.3.145

Ejemplares similares

Fludarabine-containing chemotherapy for patients with previously untreated low-grade non-Hodgkin's lymphoma
por: Ahn, Jae-Sook, et al.
Publicado: (2011)

Fludarabine phosphate for the treatment of low grade lymphoid malignancy.
por: Whelan, J. S., et al.
Publicado: (1991)

Follicular lymphoma grade 3B: low grade, high grade or should we skip the grade?
por: Mulvey, Erin, et al.
Publicado: (2023)

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation
por: Kamijo, Kimimori, et al.
Publicado: (2023)

Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells
por: Lorkova, Lucie, et al.
Publicado: (2015)

Treatment of relapsed extranodal natural killer/T-cell lymphoma with bortezomib plus fludarabine
por: Chen, Chen, et al.
Publicado: (2017)

Burkitt Lymphoma: beyond discoveries
por: Mbulaiteye, Sam M
Publicado: (2013)

Introduction to a Special Issue on Low-Grade B Cell Lymphoma in the Spleen
por: Nava, Victor E.
Publicado: (2021)

Fludarabine-based salvage therapy for refractory/relapsed acute leukemias: A single center experience
por: Abbasi, Abdul Muqtadir, et al.
Publicado: (2021)

Beyond fludarabine: pentostatin plus cyclophosphamide are a well-tolerated alternative in reduced intensity conditioning
por: Dimitrova, Dimana, et al.
Publicado: (2022)

Neurological illness following treatment with fludarabine.
por: Johnson, P. W., et al.
Publicado: (1994)

[(18)F]-Fludarabine for Hematological Malignancies
por: Barré, Louisa, et al.
Publicado: (2019)

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma
por: Scordo, Michael, et al.
Publicado: (2023)

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
por: Saraceni, Francesco, et al.
Publicado: (2017)

Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by (90)Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma
por: Pisani, Francesco, et al.
Publicado: (2015)

Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy
por: Fabrizio, Vanessa A., et al.
Publicado: (2022)

FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by (90)yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases
por: Pisani, Francesco, et al.
Publicado: (2011)

Radiation therapy for localized duodenal low-grade follicular lymphoma
por: Harada, Arisa, et al.
Publicado: (2016)

Reduced Intensity Allogeneic Hematopoietic Cell Transplantation using Fludarabine-Melphalan conditioning for Treatment of Mature T-cell Lymphomas
por: Delioukina, Maria, et al.
Publicado: (2011)

Efficacy and safety evaluation of fludarabine-based chemotherapy regimen for patients with non-Hodgkin lymphoma: A meta-analysis
por: Zhang, Xiaoping, et al.
Publicado: (2017)

Fludarabine-Melphalan-Campath, Followed by Unmanipulated Peripheral-Blood Haematopoietic Stem Cells, Can Still Cure Lymphoma
por: Avenoso, Daniele, et al.
Publicado: (2023)

Fludarabine, adriamycin and dexamethasone (FAD) in newly diagnosed advanced follicular lymphoma: a phase II study by the British National Lymphoma Investigation (BNLI)
por: Yung, L, et al.
Publicado: (2004)

Fludarabine in the treatment of chronic lymphocytic leukemia: a review
por: Ricci, Francesca, et al.
Publicado: (2009)

Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia
por: Janssens, Ann, et al.
Publicado: (2009)

Fludarabine-induced bradycardia in a patient with refractory leukemia
por: Chung-Lo, Woei, et al.
Publicado: (2010)

Ongoing trials in low-grade lymphoma
por: Burchardt, Alexander
Publicado: (2011)

Evaluation of the specificity of [(18)F]fludarabine PET/CT in a xenograft model of follicular lymphoma: comparison with [(18)F]FDG and impact of rituximab therapy
por: Hovhannisyan, Narinée, et al.
Publicado: (2015)

Fludarabine-Based Low-Intensity Conditioning for Fanconi Anemia is Associated with Good Outcomes in Aplastic Anemia but not in MDS - a Single-Center Experience
por: Chattopadhyay, Sohini, et al.
Publicado: (2023)

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
por: Sidana, Surbhi, et al.
Publicado: (2023)

T-cell large granular lymphocytic leukemia: treatment experience with fludarabine
por: Costa, Renata Oliveira, et al.
Publicado: (2012)

MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
por: Ferracin, Manuela, et al.
Publicado: (2010)

Telomerase Contributes to Fludarabine Resistance in Primary Human Leukemic Lymphocytes
por: Shawi, May, et al.
Publicado: (2013)

Aplastic Anemia Preconditioned with Fludarabine, Cyclophosphamide, and Anti-Thymocyte Globulin
por: Yang, Dan, et al.
Publicado: (2019)

Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen
por: Versluijs, A. Birgitta, et al.
Publicado: (2022)

Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party
por: Duque-Afonso, Jesus, et al.
Publicado: (2022)

New insights on low-grade and T-cell lymphoma
por: Tse, William
Publicado: (2009)

Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT
por: Bug, Gesine, et al.
Publicado: (2023)

Emerging Cellular Therapies: T Cells and Beyond
por: Todryk, Stephen, et al.
Publicado: (2019)

Beyond the survey, to the ideal therapy for Asian
por: Jo, Ki Jae, et al.
Publicado: (2023)

Lesionalized Therapy beyond Personalized Therapy in Cancer Management
por: Chung, June-Key, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jf520r1ds33ad0b1qgkqlr4o9u